middle.news

Bioxyne Surges with Record $17.2M Q2 Revenue, Eyes $75M FY26 Target

11:22am on Thursday 29th of January, 2026 AEDT Pharmaceuticals
Read Story

Bioxyne Surges with Record $17.2M Q2 Revenue, Eyes $75M FY26 Target

11:22am on Thursday 29th of January, 2026 AEDT
Key Points
  • Record $17.2 million revenue in Q2 FY2026, up 21% quarter-on-quarter
  • Entry into UK, Germany, and LATAM markets with significant growth potential
  • Positive operating cash flow of $2.5 million and $7.6 million cash on hand
  • Secured $1.6 million Scottish government grant for new UK GMP facility
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about BXN
OPEN ARTICLE